# Midostaurin (PKC412) for Locally Advanced Rectal Cancer

> **NCT01282502** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 19 (actual)

## Conditions studied

- Adenocarcinoma of the Rectum

## Interventions

- **DRUG:** Midostaurin

## Key facts

- **NCT ID:** NCT01282502
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2015-03
- **Final completion:** 2018-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2018-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01282502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01282502, "Midostaurin (PKC412) for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01282502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*